Slashdot Mirror

The parent listed subsidiary companies.

As to products to no longer buy, Bayer makes it easy. Thanks Bayer!
* Products from A to Z
* Consumer health brands
* Bayer Brands on Wikipedia.

The parent listed subsidiary companies.

As to products to no longer buy, Bayer makes it easy. Thanks Bayer!
* Products from A to Z
* Consumer health brands
* Bayer Brands on Wikipedia.

Would that be the same Bayer that sells neonicotinoids and argues against banning them?

"The bee die-offs which occurred in spring 2008 in Southwest Germany as the result of faulty application of the active ingredient clothianidin set off a controversial discussion on the use of pesticides for seed treatments."

This admission?

Last year Bayers spent €227 million to acquire 4 companies, only one of which is human health related (the other 3 are animal health and GM food related). That lone human health pharmaceutical acquisition cost €88 million, which is tiny compared to Bayer's own R&D expenses.

Taking a look at the longer term, Bayer spent €732 million in pharmaceutical related acquisitions from 2008 to 2011:
2011: €88 for Pathway Medical Technologies
2010: €0
2009: €43 for SkinMedica, Inc
2008: €601 million in total; €227 million for Possis Medical Inc, €265 for the OTC medicines division of Sagmel Inc, €109 million for Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co. Ltd

Over that same period Bayer spent €6.6 billion on in-house pharmaceutical research.

Note that the acquisitions are very sporadic. Looking at 2010 or 2008 alone for example would give very misleading results, which is why I had to sum over 4 years. Maybe if you look back further a different trend will emerge. I stopped at 2008 because it's last year with a HTML version of financial statements readily accessible. PDF versions are available all the way back to 1999.

Last year Bayers spent €227 million to acquire 4 companies, only one of which is human health related (the other 3 are animal health and GM food related). That lone human health pharmaceutical acquisition cost €88 million, which is tiny compared to Bayer's own R&D expenses.

Taking a look at the longer term, Bayer spent €732 million in pharmaceutical related acquisitions from 2008 to 2011:
2011: €88 for Pathway Medical Technologies
2010: €0
2009: €43 for SkinMedica, Inc
2008: €601 million in total; €227 million for Possis Medical Inc, €265 for the OTC medicines division of Sagmel Inc, €109 million for Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co. Ltd

Over that same period Bayer spent €6.6 billion on in-house pharmaceutical research.

Note that the acquisitions are very sporadic. Looking at 2010 or 2008 alone for example would give very misleading results, which is why I had to sum over 4 years. Maybe if you look back further a different trend will emerge. I stopped at 2008 because it's last year with a HTML version of financial statements readily accessible. PDF versions are available all the way back to 1999.

Last year Bayers spent €227 million to acquire 4 companies, only one of which is human health related (the other 3 are animal health and GM food related). That lone human health pharmaceutical acquisition cost €88 million, which is tiny compared to Bayer's own R&D expenses.

Taking a look at the longer term, Bayer spent €732 million in pharmaceutical related acquisitions from 2008 to 2011:
2011: €88 for Pathway Medical Technologies
2010: €0
2009: €43 for SkinMedica, Inc
2008: €601 million in total; €227 million for Possis Medical Inc, €265 for the OTC medicines division of Sagmel Inc, €109 million for Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co. Ltd

Over that same period Bayer spent €6.6 billion on in-house pharmaceutical research.

Note that the acquisitions are very sporadic. Looking at 2010 or 2008 alone for example would give very misleading results, which is why I had to sum over 4 years. Maybe if you look back further a different trend will emerge. I stopped at 2008 because it's last year with a HTML version of financial statements readily accessible. PDF versions are available all the way back to 1999.

Last year Bayers spent €227 million to acquire 4 companies, only one of which is human health related (the other 3 are animal health and GM food related). That lone human health pharmaceutical acquisition cost €88 million, which is tiny compared to Bayer's own R&D expenses.

Taking a look at the longer term, Bayer spent €732 million in pharmaceutical related acquisitions from 2008 to 2011:
2011: €88 for Pathway Medical Technologies
2010: €0
2009: €43 for SkinMedica, Inc
2008: €601 million in total; €227 million for Possis Medical Inc, €265 for the OTC medicines division of Sagmel Inc, €109 million for Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co. Ltd

Over that same period Bayer spent €6.6 billion on in-house pharmaceutical research.

Note that the acquisitions are very sporadic. Looking at 2010 or 2008 alone for example would give very misleading results, which is why I had to sum over 4 years. Maybe if you look back further a different trend will emerge. I stopped at 2008 because it's last year with a HTML version of financial statements readily accessible. PDF versions are available all the way back to 1999.

Last year Bayers spent €227 million to acquire 4 companies, only one of which is human health related (the other 3 are animal health and GM food related). That lone human health pharmaceutical acquisition cost €88 million, which is tiny compared to Bayer's own R&D expenses.

Taking a look at the longer term, Bayer spent €732 million in pharmaceutical related acquisitions from 2008 to 2011:
2011: €88 for Pathway Medical Technologies
2010: €0
2009: €43 for SkinMedica, Inc
2008: €601 million in total; €227 million for Possis Medical Inc, €265 for the OTC medicines division of Sagmel Inc, €109 million for Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co. Ltd

Over that same period Bayer spent €6.6 billion on in-house pharmaceutical research.

Note that the acquisitions are very sporadic. Looking at 2010 or 2008 alone for example would give very misleading results, which is why I had to sum over 4 years. Maybe if you look back further a different trend will emerge. I stopped at 2008 because it's last year with a HTML version of financial statements readily accessible. PDF versions are available all the way back to 1999.

Here's Bayer's 2011 annual report.

Last year they spent 17.975 billion euros on manufacturing, and 2.932 billion on R&D. "Selling expenses", which I assume are mostly advertising costs, was 8.958 billion. Note though that these data also include Bayer's GM food and material science divisions. Medical R&D only accounts for 66.4% of their total R&D expenses. I'm too lazy to tabulate how much of their manufacturing and advertising costs are from the medicinal division.

No offense, but all I had to do was type in bayer.com and click on the "annual report" link on their front page. All that probably took less time than typing "can anyone show me the stats".

Somewhat wrong. Research and development (R&D) is a relatively small part of the budgets of the big drug companies. Only a handful of truly important drugs have been brought to market in recent years, and they were mostly based on taxpayer-funded research at academic institutions, small biotechnology companies, or the National Institutes of Health (NIH). It sounds like you read the conservative cliff notes on the issue.

R&D expenditure varies pretty widely. Bayer appears to be one of the worst in R&D to marketing ratio; according to their 2011 Annual Report they spent about 3 billion Euros on R&D and 8.8 billion Euros on "selling" (excludes manufacturing costs). On the other hand, Roche was pretty evenly split between R&D and marketing, with about 8 billion Swiss francs on each. Bristol-Meyers Squibb put about $4.5 billion into marketing and $3.5 billion into R&D.

So yes, drug prices tend to be inflated and a lot of the expense goes to marketing. However, they are also spending a lot on R&D - generally 10% - 25% of income. I won't argue that drugs shouldn't be cheaper - they absolutely should be - but claiming that the pharmaceutical companies don't spend money on research and have no associated costs to recover above the cost of manufacturing the drugs is just plain ignorance. It is certainly worth discussing how drug research and development should be paid for, but India unilaterally deciding to ignore patents without providing any way of funding new research simply isn't sustainable if everyone does it.

It's rare that you see someone giving up rather than sueing

We do not object to use of this slang term to describe UCE, although we do object to the use of our product image in association with that term. Also, if the term is to be used, it should be used in all lower-case letters to distinguish it from our trademark SPAM, which should be used with all uppercase letters.

I know: a stack of those brown envelopes that look all official like they're from a government agency, but when you open them up - just a sales pitch?

http://www.bayer.com/en/unternehmen/historie/jung. html

The PAP-DVDs will use a thin layer of modified polymers while Holo-CDs (due out in 2005 with a said storage of 1500 GB) should have a layer of about 1 mm.

All of this is apparently part of the National Storage Industry Consortium. Unfortunately the access to the MORE project (Multiple Optical Recording Enhancements) is passworded.

Anyone got any more info?

________________________________
If encryption is outlawed, only